Posts by Dimitar V. Zlatev, MD
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
Biography
Dimitar Zlatev, MD, MS, is a urologic oncologist at the Massachusetts General Hospital Department of Urology and Harvard Medical School. He is a urologic surgeon who specializes in the treatment of genitourinary cancers using open, robotic, laparoscopic, and endoscopic surgical techniques. His research focuses on the application of computational methods to the analysis, interpretation, and utilization of oncology data for genitourinary malignancies.
Dr. Zlatev is a faculty member of the Department of Urology and a Urologic Oncologist at Mass General. He holds a Master of Science in Computer Science from Tufts University, with an emphasis on computational biology. He earned his MD from Northwestern University and trained in General Surgery and Urology at Stanford University. He completed fellowship in Urologic Oncology at the Combined Harvard Fellowship at Mass General and Brigham and Women’s Hospital, where he was awarded the best clinical research award at the annual Harvard Medical School Surgery Research conference.
Dr. Zlatev's clinical practice focuses on the surgical treatment of genitourinary cancers, with a particular emphasis on bladder cancer, prostate cancer, and kidney cancer. He utilizes all available surgical techniques, including open, robotic, laparoscopic, and endoscopic surgery. His research interests focus on the utilization of computer science and computational biology methods to gain insight into improving and optimizing the perioperative care of patients undergoing surgical treatment for genitourinary cancers.
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
